Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Rinvoq
Rinvoq
AbbVie's Gonzalez: Skyrizi and Rinvoq to become Humira 2.0 — while adding an indication for atopic dermatitis
Endpoints
Wed, 02/2/22 - 11:46 pm
AbbVie
earnings
Rick Gonzalez
Skyrizi
Rinvoq
What This FDA News Could Mean for AbbVie's Stock
Motley Fool
Mon, 01/24/22 - 10:10 am
AbbVie
Rinvoq
FDA
JPM 2022: AbbVie adjusts 2025 individual sales projections for Rinvoq and Skyrizi but not their combined total of $15B
Fierce Pharma
Thu, 01/13/22 - 11:00 am
AbbVie
Rinvoq
Skyrizi
JPMHC 2022
Could This FDA Approval Create a Blockbuster Drug for AbbVie?
Motley Fool
Sun, 01/2/22 - 11:36 pm
AbbVie
Rinvoq
FDA
psoriatic arthritis
What to Make of the FDA's Latest Warning to AbbVie and Pfizer
Motley Fool
Sat, 12/18/21 - 10:56 pm
FDA
AbbVie
Pfizer
Rinvoq
Xeljanz
JAK inhibitors
Amid safety concerns, FDA grants two new JAK approvals — but with added warnings and a key label change
Endpoints
Wed, 12/15/21 - 10:52 am
Pfizer
AbbVie
Xeljanz
Rinvoq
FDA
JAK inhibitors
AbbVie's Rinvoq notches Crohn's disease win amid classwide JAK safety concerns
Fierce Pharma
Mon, 12/6/21 - 11:45 pm
AbbVie
Rinvoq
Crohn’s disease
Even AbbVie CEO can't confirm Rinvoq's sales as FDA mulls JAK label
Fierce Pharma
Mon, 11/1/21 - 10:55 am
AbbVie
Pharma CEOs
Rick Gonzalez
Rinvoq
FDA
AbbVie touts more Rinvoq data in inflammatory spinal arthritis as it awaits key FDA decisions
Fierce Pharma
Thu, 10/7/21 - 12:25 pm
AbbVie
Rinvoq
FDA
inflammatory spinal arthritis
AbbVie's stock and next megablockbuster take hits following new JAK warnings from FDA
Endpoints
Wed, 09/1/21 - 11:16 pm
AbbVie
Pfizer
Rinvoq
JAK inhibitors
FDA
AbbVie’s Rinvoq is first JAK drug cleared in EU for atopic dermatitis
Pharmaforum
Wed, 08/25/21 - 09:19 pm
AbbVie
Rinvoq
Europe
atopic dermatitis
FDA
AbbVie's post-Humira stalwarts Skyrizi, Rinvoq performing exactly as hoped, CEO says
Fierce Pharma
Sat, 07/31/21 - 10:07 pm
AbbVie
earnings
Humira
Skyrizi
Rinvoq
AbbVie, Lilly Atopic Dermatitis Treatments Hit With Further Delays With FDA
Yahoo/Benzinga
Sun, 07/18/21 - 09:45 pm
AbbVie
Eli Lilly
atopic dermatitis
FDA
Rinvoq
olumiant
AbbVie says Rinvoq shines again as maintenance therapy for ulcerative colitis — but safety concerns still loom over JAK class
Endpoints
Wed, 06/30/21 - 10:49 am
AbbVie
ulcerative colitis
clinical trials
Rinvoq
Key third-quarter readouts for big pharma
EP Vantage
Tue, 06/29/21 - 10:59 am
clinical trials
Pfizer
Roche
idanacogene elaparvovec
Alexion
AstraZeneca
Ultomiris
AbbVie
Rinvoq
Novartis
sabatolimab
AbbVie (ABBV) Announces FDA Will Not Meet PDUFA Action Dates for RINVOQ sNDAs
Street Insider
Fri, 06/25/21 - 11:12 am
AbbVie
FDA
Rinvoq
psoriatic arthritis
AbbVie, building out its post-Humira future, posts 5 late-stage trial wins for Skyrizi and Rinvoq
Fierce Pharma
Wed, 05/26/21 - 12:05 pm
AbbVie
Humira
drug pricing
patents
immunology
Skyrizi
Rinvoq
clinical trials
Crohn's Disease
atopic dermatitis
AbbVie's Rinvoq rollout on track despite JAK safety concerns, but uncertainty remains: analyst
Fierce Pharma
Thu, 04/22/21 - 11:42 pm
AbbVie
Rinvoq
Xeljanz
FDA
rheumatoid arthritis
Series of JAK inhibitor delays may signal an upcoming FDA adcomm
Endpoints
Thu, 04/8/21 - 11:10 am
FDA
JAK inhibitors
AbbVie
Rinvoq
Pfizer
Xeljanz
Eli Lilly
olumiant
AbbVie's Rinvoq expansion hits a 2nd snag as FDA delays $2B atopic dermatitis ruling
Fierce Pharma
Mon, 04/5/21 - 02:47 pm
AbbVie
Rinvoq
Humra
FDA
Pages
« first
‹ previous
1
2
3
next ›
last »